Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response

Abstract

The majority of advanced, treatment-resistant tumors across tumor types harbor biologically informative alterations. The establishment of a clinical trial for WES of metastatic tumors with prospective follow-up of patients can help identify candidate predictive biomarkers of response.